Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Twist Bioscience Co. (NASDAQ:TWST) by 132.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,815 shares of the company’s stock after purchasing an additional 14,157 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Twist Bioscience were worth $1,153,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TWST. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience in the third quarter valued at $34,000. US Bancorp DE lifted its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience during the 3rd quarter worth $95,000. Finally, KBC Group NV increased its position in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TWST shares. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 806 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. This represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,799 shares of company stock valued at $1,593,944. Insiders own 3.01% of the company’s stock.

Twist Bioscience Price Performance

TWST stock opened at $41.58 on Friday. The business’s 50-day moving average is $45.30 and its two-hundred day moving average is $45.31. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The firm has a market capitalization of $2.48 billion, a P/E ratio of -12.30 and a beta of 2.15. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter last year, the company earned ($0.75) earnings per share. The firm’s revenue was up 24.1% compared to the same quarter last year. Analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.